Citizens Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX) Ahead of Ph1 Results
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)